You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
|
|---|---|
| Published in |
Nature Medicine, July 2018
|
| DOI | 10.1038/s41591-018-0101-z |
| Pubmed ID | |
| Authors |
Seung Tae Kim, Razvan Cristescu, Adam J. Bass, Kyoung-Mee Kim, Justin I. Odegaard, Kyung Kim, Xiao Qiao Liu, Xinwei Sher, Hun Jung, Mijin Lee, Sujin Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Hyuk Lee, Mingew Choi, AmirAli Talasaz, Peter Soonmo Kang, Jonathan Cheng, Andrey Loboda, Jeeyun Lee, Won Ki Kang |
| Abstract |
Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a subset of patients with metastatic gastric cancer (mGC). With the goal of identifying determinants of response, we performed molecular characterization of tissues and circulating tumor DNA (ctDNA) from 61 patients with mGC who were treated with pembrolizumab as salvage treatment in a prospective phase 2 clinical trial. In patients with microsatellite instability-high and Epstein-Barr virus-positive tumors, which are mutually exclusive, dramatic responses to pembrolizumab were observed (overall response rate (ORR) 85.7% in microsatellite instability-high mGC and ORR 100% in Epstein-Barr virus-positive mGC). For the 55 patients for whom programmed death-ligand 1 (PD-L1) combined positive score positivity was available (combined positive score cut-off value ≥1%), ORR was significantly higher in PD-L1(+) gastric cancer when compared to PD-L1(-) tumors (50.0% versus 0.0%, P value <0.001). Changes in ctDNA levels at six weeks post-treatment predicted response and progression-free survival, and decreased ctDNA was associated with improved outcomes. Our findings provide insight into the molecular features associated with response to pembrolizumab in patients with mGC and provide biomarkers potentially relevant for the selection of patients who may derive greater benefit from PD-1 inhibition. |
X Demographics
The data shown below were collected from the profiles of 198 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 54 | 27% |
| United Kingdom | 15 | 8% |
| Spain | 13 | 7% |
| Canada | 8 | 4% |
| Brazil | 6 | 3% |
| Germany | 5 | 3% |
| Australia | 4 | 2% |
| India | 3 | 2% |
| Sweden | 2 | 1% |
| Other | 26 | 13% |
| Unknown | 62 | 31% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 92 | 46% |
| Scientists | 76 | 38% |
| Practitioners (doctors, other healthcare professionals) | 28 | 14% |
| Science communicators (journalists, bloggers, editors) | 1 | <1% |
| Unknown | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 628 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 628 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 129 | 21% |
| Student > Ph. D. Student | 92 | 15% |
| Other | 47 | 7% |
| Student > Master | 43 | 7% |
| Student > Doctoral Student | 34 | 5% |
| Other | 104 | 17% |
| Unknown | 179 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 179 | 29% |
| Biochemistry, Genetics and Molecular Biology | 96 | 15% |
| Agricultural and Biological Sciences | 49 | 8% |
| Immunology and Microbiology | 36 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 19 | 3% |
| Other | 57 | 9% |
| Unknown | 192 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 616. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 January 2024.
All research outputs
#37,202
of 25,775,807 outputs
Outputs from Nature Medicine
#268
of 9,432 outputs
Outputs of similar age
#744
of 340,727 outputs
Outputs of similar age from Nature Medicine
#9
of 130 outputs
Altmetric has tracked 25,775,807 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,432 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 105.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,727 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 130 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.